Keyphrases
Prevention Strategies
100%
Diffuse Large B-cell Lymphoma (DLBCL)
100%
Central Nervous System Involvement
100%
Risk Analysis
100%
Risk Strategy
100%
Post-rituximab
100%
Chemoimmunotherapy
100%
Rituximab Era
100%
High Risk
66%
Extranodal Sites
66%
Kidney
33%
Breast
33%
Testicle
33%
Clinical High Risk
33%
Flow Cytometry
33%
Treatment Strategy
33%
Rituximab
33%
Lactate Dehydrogenase
33%
Chemotherapy Regimen
33%
High-risk Population
33%
Central Nervous System Recurrence
33%
Nervous System Diseases
33%
Detection Method
33%
Risk Treatment
33%
Epidural Space
33%
Central Nervous System Relapse
33%
Elevated Lactate
33%
Risk Factor Assessment
33%
High-risk Features
33%
High-dose Methotrexate (HD-MTX)
33%
Intrathecal Prophylaxis
33%
Orbit Space
33%
Medicine and Dentistry
Diffuse Large B-Cell Lymphoma
100%
Rituximab
100%
Central Nervous System
100%
Chemoimmunotherapy
100%
Flow Cytometry
33%
Drug Megadose
33%
Recurrent Disease
33%
Systematic Review
33%
Testes
33%
High Risk Population
33%
Methotrexate
33%
Central Nervous System Disease
33%
Lactate Dehydrogenase
33%
Epidural Space
33%
Chemotherapy
33%
Pharmacology, Toxicology and Pharmaceutical Science
Diffuse Large B Cell Lymphoma
100%
Rituximab
100%
Chemotherapy
33%
Recurrent Disease
33%
Intrathecal
33%
Flow Cytometry
33%
Lactate Dehydrogenase
33%
Methotrexate
33%
Central Nervous System Disease
33%
Immunology and Microbiology
B Cell
100%
Central Nervous System
100%
Rituximab
100%
Drug Megadose
25%
Methotrexate
25%
High Risk Population
25%
Testis
25%
Epidural Space
25%